Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

(2015) Yuchen Jiao et al.   Oncotarget

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma

(2015) Kasthuri Kannan et al.   Oncotarget

Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma

(2014) Benedikt Wiestler et al.   ACTA NEUROPATHOLOGICA

Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial

(2014) B. Wiestler et al.   NEURO-ONCOLOGY

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis

(2013) Benedikt Wiestler et al.   ACTA NEUROPATHOLOGICA

CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas

(2012) Felix Sahm et al.   ACTA NEUROPATHOLOGICA

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

(2012) Xiao-Yang Liu et al.   ACTA NEUROPATHOLOGICA

Chromogenicin situHybridization is a Reliable Alternative to Fluorescencein situHybridization for Diagnostic Testing of 1p and 19q Loss in Paraffin-Embedded Gliomas

(2012) Ulrike Lass et al.   BRAIN PATHOLOGY

Molecular and Morphologic Correlates of the Alternative Lengthening of Telomeres Phenotype in High-Grade Astrocytomas

(2012) Doreen N. Nguyen et al.   BRAIN PATHOLOGY

Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma

(2012) Dominik Sturm et al.   CANCER CELL

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

(2012) Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

(2012) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

(2012) Jeremy Schwartzentruber et al.   NATURE

Clonal Analysis in Recurrent Astrocytic, Oligoastrocytic and Oligodendroglial Tumors Implicates IDH1- Mutation as Common Tumor Initiating Event

(2012) Ulrike Lass et al.   PLoS One

Application of Mutant IDH1 Antibody to Differentiate Diffuse Glioma From Nonneoplastic Central Nervous System Lesions and Therapy-induced Changes

(2010) David Capper et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Scientific correspondence

(2010) S. Pusch et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Monoclonal antibody specific for IDH1 R132H mutation

(2009) David Capper et al.   ACTA NEUROPATHOLOGICA

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis

(2009) Sandra Camelo-Piragua et al.   ACTA NEUROPATHOLOGICA

Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors

(2009) David Capper et al.   BRAIN PATHOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of the IDH1 codon 132 mutation in brain tumors

(2008) Jörg Balss et al.   ACTA NEUROPATHOLOGICA